Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 2/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.41 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.41 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.41 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26178852 | 0.93 | SRC (0.49) | SRCCGASPDGFRBPDGFRATGFBR1 | |
| SCHEMBL29387468 | 0.88 | SRC (0.60) | SRCCGASPDGFRBPDGFRAEGFR | |
| SCHEMBL29576504 | 0.88 | SRC (0.60) | SRCCGASPDGFRBPDGFRAEGFR | |
| SCHEMBL359988 | 0.88 | SRC (0.60) | SRCCGASPDGFRBPDGFRAEGFR | |
| Hydrochloric Acid SCHEMBL6432173 | 0.86 | SRC (0.58) | SRCCGASPDGFRBPDGFRAEGFR | |
| SCHEMBL6004164 | 0.86 | CGAS (0.59) | SRCCGASPDGFRBPDGFRAEGFR | |
| SCHEMBL24008989 | 0.83 | SRC (0.58) | SRCCGASPDGFRBPDGFRAEGFR | |
| SCHEMBL6002911 | 0.82 | TLR8 (0.43) | SRC | |
| SCHEMBL22766354 | 0.82 | SRC (0.48) | SRCCGASPDGFRBPDGFRAEGFR | |
| SCHEMBL29612582 | 0.82 | SRC (0.48) | SRCCGASPDGFRBPDGFRAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-12 | — | — | US | disclosed |
| US-9938274-B1 | Naphthyridine compounds, medical combinations and use thereof | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9877970-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9695184-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NPM1, NEK4, NME1 | SRC 697/4885CGAS 558/4885PDGFRB 4024/4885 |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | SRC 399/4885CGAS 1697/4885PDGFRB 16/4885 |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885CGAS 1387/4885PDGFRB 2819/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | SRC 496/4885CGAS 2260/4885PDGFRB 14/4885 |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885CGAS 1387/4885PDGFRB 2819/4885 |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885CGAS 1387/4885PDGFRB 2819/4885 |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885CGAS 1387/4885PDGFRB 2819/4885 |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | PCSK9, CFTR, SLC10A1 | SRC 2335/4885CGAS 2010/4885PDGFRB 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.